ATE504653T1 - Vaccinia virus wirtspektrum gene zur erhöhung des titers von avipoxviren - Google Patents

Vaccinia virus wirtspektrum gene zur erhöhung des titers von avipoxviren

Info

Publication number
ATE504653T1
ATE504653T1 AT03784104T AT03784104T ATE504653T1 AT E504653 T1 ATE504653 T1 AT E504653T1 AT 03784104 T AT03784104 T AT 03784104T AT 03784104 T AT03784104 T AT 03784104T AT E504653 T1 ATE504653 T1 AT E504653T1
Authority
AT
Austria
Prior art keywords
vaccinia virus
avipoxviruses
host range
increasing
cells
Prior art date
Application number
AT03784104T
Other languages
English (en)
Inventor
Paul Howley
Christine Meisinger-Henschel
Original Assignee
Bavarian Nordic As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bavarian Nordic As filed Critical Bavarian Nordic As
Application granted granted Critical
Publication of ATE504653T1 publication Critical patent/ATE504653T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86Viral vectors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525Virus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/24011Poxviridae
    • C12N2710/24111Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24122New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/24011Poxviridae
    • C12N2710/24111Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00Vector systems having a special element relevant for transcription
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00Vector systems having a special element relevant for transcription
    • C12N2830/15Vector systems having a special element relevant for transcription chimeric enhancer/promoter combination
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00Vector systems having a special element relevant for transcription
    • C12N2830/60Vector systems having a special element relevant for transcription from viruses
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00Vectors comprising a special translation-regulating system
    • C12N2840/20Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Transplantation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT03784104T 2002-08-07 2003-07-29 Vaccinia virus wirtspektrum gene zur erhöhung des titers von avipoxviren ATE504653T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA200201189 2002-08-07
PCT/EP2003/008359 WO2004015118A1 (en) 2002-08-07 2003-07-29 Vaccinia virus host range genes to increase the titer of avipoxviruses

Publications (1)

Publication Number Publication Date
ATE504653T1 true ATE504653T1 (de) 2011-04-15

Family

ID=31502636

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03784104T ATE504653T1 (de) 2002-08-07 2003-07-29 Vaccinia virus wirtspektrum gene zur erhöhung des titers von avipoxviren

Country Status (8)

Country Link
US (2) US7473536B2 (de)
EP (2) EP1529113B1 (de)
JP (1) JP2005534326A (de)
AT (1) ATE504653T1 (de)
AU (1) AU2003255315A1 (de)
CA (1) CA2489301A1 (de)
DE (1) DE60336653D1 (de)
WO (1) WO2004015118A1 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7501127B2 (en) 2002-05-16 2009-03-10 Bavarian Nordic A/S Intergenic regions as novel sites for insertion of HIV DNA sequences in the genome of Modified Vaccinia virus Ankara
ATE504653T1 (de) * 2002-08-07 2011-04-15 Bavarian Nordic As Vaccinia virus wirtspektrum gene zur erhöhung des titers von avipoxviren
EP1528101A1 (de) 2003-11-03 2005-05-04 ProBioGen AG Immortalisierte Vogel-Zelllinien für die Produktion von Viren
DK1536015T3 (da) * 2003-11-24 2008-02-18 Bavarian Nordic As Promotorer til ekspression i modificeret vacciniavirus Ankara
ES2315096B1 (es) * 2006-05-13 2009-12-30 Consejo Superior De Investigaciones Cientificas Vectores en los que se inserta el gen c7l y uso de los mismos en la fabricacion de vacunas y de composiciones para terapia genica.
WO2007136763A2 (en) * 2006-05-19 2007-11-29 Sanofi Pasteur, Inc. Immunological composition
EP2424999A1 (de) 2009-04-30 2012-03-07 Centre Hospitalier Universitaire Vaudois Lausanne (CHUV) Modifizierte immunisierungsvektoren
EP2668201A2 (de) 2011-01-28 2013-12-04 Sanofi Pasteur SA Immunologische zusammensetzungen mit hiv-gp41-polypeptidderivaten
WO2014140938A2 (en) 2013-03-14 2014-09-18 Centre Hospitalier Universitaire Vaudois Immunological methods
TR201807128T4 (tr) * 2013-11-01 2018-06-21 Sementis Ltd Viral vektör imalatı.
AU2019319832A1 (en) * 2018-08-08 2021-03-25 Arizona Board Of Regents On Behalf Of Arizona State University Method for improved poxvirus yields
CN117651774A (zh) * 2021-06-30 2024-03-05 礼富利科技股份有限公司 负链rna病毒载体的制造方法和所制造的负链rna病毒载体

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE787901A (fr) 1971-09-11 1972-12-18 Freistaat Bayern Represente Pa Vaccin antivariolique
US5833975A (en) 1989-03-08 1998-11-10 Virogenetics Corporation Canarypox virus expressing cytokine and/or tumor-associated antigen DNA sequence
US4603112A (en) 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
US5505941A (en) 1981-12-24 1996-04-09 Health Research, Inc. Recombinant avipox virus and method to induce an immune response
JPH0795954B2 (ja) 1982-11-30 1995-10-18 アメリカ合衆国 外来性遺伝子発現のためのポックスウイルス組換え体の製造方法
ATE247163T1 (de) * 1991-03-07 2003-08-15 Virogenetics Corp Gentechnologisch hergestellter stamm für impfstoffe
US5766598A (en) 1991-03-07 1998-06-16 Virogenetics Corporation Recombinant attenuated ALVAC canarypoxvirus expression vectors containing heterologous DNA segments encoding lentiviral gene products
EP0951555A2 (de) 1996-09-24 1999-10-27 Bavarian Nordic Research Institute A/S Rekombinantes mva-virus das dengue-virus antigene exprimiert und dessen verwendung in impfstoffen
US5990091A (en) * 1997-03-12 1999-11-23 Virogenetics Corporation Vectors having enhanced expression, and methods of making and uses thereof
US6004777A (en) * 1997-03-12 1999-12-21 Virogenetics Corporation Vectors having enhanced expression, and methods of making and uses thereof
US6294176B1 (en) * 1998-07-10 2001-09-25 Schering-Plough Veterinary Corp. Recombinant raccoonpox virus and uses thereof as a vaccine in mammalian and avian species
FR2811766B1 (fr) 2000-07-13 2002-09-27 Tabacs & Allumettes Ind Procede de caracterisation de la compacite d'objets tels que des cigarettes ou des filtres
AU2002246829A1 (en) * 2000-12-22 2002-07-30 The Government Of The United States Of America, Represented By The Secretary, Department Of Health A Methods to control the host range of retroviral vectors
ATE504653T1 (de) * 2002-08-07 2011-04-15 Bavarian Nordic As Vaccinia virus wirtspektrum gene zur erhöhung des titers von avipoxviren

Also Published As

Publication number Publication date
CA2489301A1 (en) 2004-02-19
EP2264178A1 (de) 2010-12-22
US20090162935A1 (en) 2009-06-25
JP2005534326A (ja) 2005-11-17
AU2003255315A1 (en) 2004-02-25
WO2004015118A1 (en) 2004-02-19
US20060039928A1 (en) 2006-02-23
DE60336653D1 (de) 2011-05-19
EP1529113B1 (de) 2011-04-06
EP1529113A1 (de) 2005-05-11
US7473536B2 (en) 2009-01-06

Similar Documents

Publication Publication Date Title
ATE504653T1 (de) Vaccinia virus wirtspektrum gene zur erhöhung des titers von avipoxviren
DE69737886D1 (de) Infektioese rna virus-klone, vakzine und davon abgeleitete diagnostische assays
BRPI0309631A8 (pt) vacina tetravalente da dengue contendo uma trivial deleção de 30 nucleotídeos na utr-31' dos tipos de dengue 1,2,3 e 4, ou de vírus antigênicos quiméricos da dengue 1,2,3 e 4
DK0702085T4 (da) Rekombinant infektiøs ikke-segmenteret negativ-strenget RNA-virus
EA200201164A1 (ru) Система трансфекции днк для получения инфекционного вируса гриппа
DE122008000035I1 (de) Rekombinante influenzaviren zur vakzinherstellung und gentherapie
WO2006136448A3 (en) Attenuated sars and use as a vaccine
WO2005014806A3 (en) Conserved hbv and hcv sequences useful for gene silencing
NO20032309L (no) Modifisert variant av vaccinia ankaravirus
ATE507293T1 (de) Zum gen-silencing geeignete konservierte hbv- und hcv-sequenzen
RS50977B (sr) Replikaciono defektni rnk-virusi kao vakcine
WO2003023040A3 (en) Vaccinia virus mva-e3l-knockout-mutants and use thereof
DE60320520D1 (de) Verfahren zur amplifikation von einem poxvirus in serumfreien verhältnissen
AU7411694A (en) Viruses and their use as a vaccine against feline infectious peritonitis virus disease
UA84667C2 (ru) Вакцина, направленная против инфекции, вызванной вирусом герпеса болезни марека
WO2003106641A3 (en) IDENTIFICATION OF OLIGONUCLEOTIDES FOR CAPTURE, DETECTION AND QUANTIFICATION OF NUCLEIC ACIDS FROM HEPATITIS A VIRUS
DK1356062T3 (da) Frembringelse af rekombinanter af kunstigt gærkromosom af human cytomegalovirus
IL164179A0 (en) Expression of genes in modified vaccinia virus ankara by using the cowpox ati promoter
JP2005534326A5 (de)
EA200601218A1 (ru) Респираторно-синцитиальный вирус с перекрёстно компенсированным геномным дефицитом
WO2007038316A3 (en) Human cytomegalovirus latency promoting genes, related virus variants and methods of use
DE60035680D1 (de) Komplette gensequenz des esel-leukozyten-impfstoffstammes des equinen infektiösen anemievirus und ihre anwendung
WO2001011065A3 (en) Hepatitis a virus clones adapted for growth in agmk cells
WO1997040166A3 (en) Simian-human hav having a chimeric 2c protein
EP1331270A4 (de) Neuer rekombinanter katzen-herpesvirus 1 und dessen verwendung in einem polyvalenten impfstoff

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties